drugset / Trial / NCT05607953
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
This study is an open-label, phase 1/1b study of the pressure-enabled intrapancreatic infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with locally advanced pancreatic cancer.
Timeline
- Start
- 2023-03-01
- Primary completion
- 2027-09
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nelitolimod | Oligonucleotide (other) | 0.5 mg | Other |
| Subject | Nelitolimod | Oligonucleotide (other) | 2 mg | Other |
| Subject | Nelitolimod | Oligonucleotide (other) | 4 mg | Other |
| Subject | Nelitolimod | Oligonucleotide (other) | 8 mg | Other |